The estimated Net Worth of Ann M. Leen is at least $7.13 millió dollars as of 12 November 2021. Dr Leen owns over 20,988 units of AlloVir stock worth over $1,738,997 and over the last 5 years he sold ALVR stock worth over $5,391,174.
Dr has made over 7 trades of the AlloVir stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 20,988 units of ALVR stock worth $465,514 on 12 November 2021.
The largest trade he's ever made was selling 150,000 units of AlloVir stock on 10 May 2021 worth over $3,412,500. On average, Dr trades about 17,418 units every 22 days since 2020. As of 12 November 2021 he still owns at least 2,288,154 units of AlloVir stock.
You can see the complete history of Dr Leen stock trades at the bottom of the page.
Dr. Ann M. Leen Ph.D. is the Chief Scientific Officer at AlloVir.
Dr D is 44, he's been the Chief Scientific Officer of AlloVir since . There are 9 older and no younger executives at AlloVir. The oldest executive at AlloVir, Inc. is Vikas Sinha C.A., CPA, M.B.A., 58, who is the Pres, CFO & Director.
Ann's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... és Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
AlloVir executives and other stock owners filed with the SEC include: